(Prostate Cancer) Is Talazoparib + Enzalutamide Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- February 27, 2023
- Read time: 1 minute
From February 16–18, 2023, Neeraj Agarwal of Huntsman Cancer Institute and colleagues presented at ASCO GU 2023 in San Francisco, California, the efficacy and safety results of Talazoparib + Enzalutamide as first-line treatment in metastatic castration-resistant prostate cancer patients in the TALAPRO-2 Phase 3 clinical trial.
The TALAPRO-2 Phase 3 clinical trial was a randomized, double-blind trial that randomized metastatic castration-resistant prostate cancer patients (N=805) to either Talazoparib (once daily, 0.5 mg) + Enzalutamide (160 mg) group (N=402) or placebo group (N=403). The primary endpoint was radiographic progression-free survival, and secondary endpoints were overall survival, objective response rate, and PSA index.
The results showed that the median radiographic progression-free survival was: Talazoparib + Enzalutamide group: not reached / placebo group: 21.9 months. HRR-deficient patients in the Talazoparib + Enzalutamide group showed a 54% reduction in risk of radiographic progression or death compared to the placebo group. Patients without HRR deficiency in the Talazoparib + Enzalutamide group showed a 30% reduction in risk, while secondary endpoint data were not yet mature.
Regarding safety, the incidence of Grade 3–4 adverse events was: Talazoparib + Enzalutamide group 71.9% / placebo group 40.6%. Grade 3 or higher adverse events observed between groups were: Talazoparib + Enzalutamide group — anemia, neutropenia, and thrombocytopenia; placebo group — hypertension, anemia, and fatigue.
Based on the TALAPRO-2 trial results, Talazoparib + Enzalutamide as first-line treatment in metastatic castration-resistant prostate cancer patients improved radiographic progression-free survival regardless of HRR deficiency status.
Source: https://meetings.asco.org/abstracts-presentations/216877
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4